Arcutis Biotherapeutics, Inc.

  • Moat Score
  • Safety Score
  • Market Cap $1.22B
  • PE -6
  • Debt $304.12M
  • Cash $135.47M
  • EV $1.39B
  • FCF -$167.80M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$195.54M
EBIT-$179.26M
ROE-125%
ROA-41%
FCF-$167.80M
Equity$156.64M
Growth Stability1
PE-6.24
PB7.79
P/FCF-7.28
P/S8.8
Price/Cash0.11
Debt/Equity1.94
Debt/FCF-1.81
Net Margins-103%
Gross Margins90%
Op. Margins-129%
Sales Growth YoY17%
Sales Growth QoQ45%
Sales CAGR19%
Equity CAGR-19%
Earnings Growth YoY-7%
Earnings Growth QoQ-21%
Sales CAGR 5Y57%
Equity CAGR 5Y-20%
Earnings CAGR 3Y1K%
Sales CAGR 3Y1K%
Equity CAGR 3Y-24%
Market Cap$1.22B
Revenue$138.71M
Assets$437.35M
Total Debt$304.12M
Cash$135.47M
Shares Outstanding117M
EV1.39B
Moat Score1%
Safety Score60%
Working Capital251.29M
Current Ratio2.46
Shares Growth 3y20%
Equity Growth QoQ-16%
Equity Growth YoY235%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

SEC Filings

Direct access to Arcutis Biotherapeutics, Inc. (ARQT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Arcutis Biotherapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Arcutis Biotherapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Arcutis Biotherapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Arcutis Biotherapeutics, Inc..

= -$1.7B
012345678910TV
fcf-$168M-$168M-$168M-$168M-$168M-$168M-$168M-$168M-$168M-$168M-$168M-$1.7B
DCF-$153M-$139M-$126M-$115M-$104M-$95M-$86M-$78M-$71M-$65M-$647M
Value-$1.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/2023TTM
Net Margins-----8K%-440%-103%
ROA--40%-46%-51%-66%-67%-41%
ROE-65%-50%-69%-149%-296%-125%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/2023TTM
Debt over FCF---0-0.46-0.78-0.82-1.81
Debt over Equity--00.270.952.281.94
Growth Stability------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-----2K%57%
Earnings YoY growth-118%223%52%51%-16%-
Equity YoY growth-171%-516%10%-30%-58%-20%
FCF YoY growth-206%163%55%47%-4%-